Taiho and Cullinan renegotiate rights to lung cancer candidate

12 May 2022

Tokyo’s Taiho Pharmaceutical, a business of Japanese drug major Otsuka Pharmaceutical (TYO: 4768), has agreed to buy part of Cullinan Oncology (Nasdaq: CGEM), thereby regaining rights to a candidate it out-licensed in 2019.

Through acquiring the subsidiary Cullinan Pearl, Taiho will pick up rights to co-develop and co-commercialize the American firm’s lead program, CLN-081, in the USA.

Having previously sold rights to Cullinan, Taiho will now regain a license for exclusive worldwide ex-Japanese development and commercialization, paying $275 million upfront. Taiho will also agree to pay up to an additional $130 million tied to regulatory milestones in this indication.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK